Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate

• Published in: Vaccine Vol. 25; no. 50; pp. 8460 - 8468
• Main Authors: Junco, Jesús A, Peschke, Peter, Zuna, Ivan, Ehemann, Volker, Fuentes, Franklin, Bover, Eddy, Pimentel, Eulogio, Basulto, Roberto, Reyes, Osvaldo, Calzada, Lesvia, Castro, María D, Arteaga, Niurka, López, Yovisleidis, Garay, Hilda, Hernández, Héctor, Bringas, Ricardo, Guillén, Gerardo E
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 05.12.2007; Elsevier; Elsevier Limited
• Subjects: Adjuvants, Immunologic - administration & dosage; Allergy and Immunology; Animals; Antibodies - blood; Applied microbiology; Biological and medical sciences; Cancer therapies; Cancer vaccines; Cancer Vaccines - administration & dosage; Cancer Vaccines - immunology; Cell Line, Tumor; Clinical trials; Disease Models, Animal; Fundamental and applied biological sciences. Psychology; Gonadotropin-Releasing Hormone - administration & dosage; Gonadotropin-Releasing Hormone - immunology; Hormone-sensitive prostate cancer; Humans; Immunization; Immunotherapy; Laboratory animals; Male; Mannitol - administration & dosage; Mannitol - analogs & derivatives; Mannitol - immunology; Medical research; Medical sciences; Microbiology; Oleic Acids - administration & dosage; Oleic Acids - immunology; Peptide Fragments - administration & dosage; Peptide Fragments - chemical synthesis; Peptide Fragments - immunology; Peptides; Prostate cancer; Prostatic Neoplasms - immunology; Prostatic Neoplasms - mortality; Prostatic Neoplasms - prevention & control; Prostatic Neoplasms - therapy; Rats; Rodents; Testosterone; Testosterone - blood; Tetanus Toxoid - administration & dosage; Tetanus Toxoid - immunology; Tumors; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology; Cancer vaccines; Hormone-sensitive prostate cancer; Immunotherapy; Hormone; Animal model; Urinary system disease; Prostate disease; Vaccine; Malignant tumor; Male genital diseases; Prostate cancer; Cancer
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2007.09.033

Abstract Previous studies with gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate cancer. To this end, we have generated a completely synthetic peptide modified at position 6 and attached to the 830–844 tetanic toxoid (TT) helper T cell sequence. Through this work we have demonstrated that the GnRHm1-TT molecule was highly immunogenic when it is formulated as an oil-based emulsion adjuvated with Montanide ISA 51. That results correlated directly with testosterone reduction and tumor growth inhibition of the Dunning R3327-H androgen responsive prostate tumor model in rats. GnRHm1-TT, proved to be safe and useful for future clinical trials.